Dyslipidemia and Cardiovascular Disease: The Dawn of an Era with New Targets and Novel Therapies

Dear Colleagues,

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of worldwide mortality and dyslipidemia is a major risk factor. Despite the available lipid-lowering therapies, a considerable proportion of patients with dyslipidemias remain undiagnosed or undertreated. Even patients achieving optimal low-density lipoprotein (LDL) cholesterol levels might still develop a major ASCVD event. This residual ASCVD risk might be attributed to the late initiation of lipid-lowering therapies and lacking control of emerging ASCVD risk factors, such as triglyceride-rich lipoproteins, lipoprotein (a), obesity, or inflammation. In this context, the implementation of therapeutic strategies preventing or reducing cumulative exposure to apolipoprotein B cholesterol-containing lipoproteins and other residual ASCVD risk factors, along with the emergence of novel therapies might provide new opportunities to prevent ASCVD.

With this Special Issue, we are pleased to welcome authors to submit original research articles and comprehensive reviews covering current and evolving aspects of dyslipidemias in the setting of ASCVD prevention.

Dr. Fotios Barkas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.